AGC Biologics Inks Supply Deal for COVID-19 Vaccine. AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has partnered with BioNTech SE to supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
“We are honored that BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,” said Mark Womack, chief business officer, AGC Biologics. “We are very proud of our efforts to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the COVID-19 pandemic.” BioNTech to Build Covid-19 Vaccine Facility in Singapore By 2023. German vaccine developer BioNTech SE selected Singapore as its Southeast Asia headquarters and first Asia-Pacific hub, giving a boost to supply of an mRNA vaccine that’s been extraordinarily effective in fighting Covid-19.
The production site could be operational as early as 2023 and will create as many as 80 jobs in Singapore, the company said in a statement Monday. The Mainz, Germany-based BioNTech said the planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide rapid-response options for Southeast Asia against potential future pandemic threats. BioNTech’s Covid vaccine, co-developed with American pharmaceutical giant Pfizer Inc., has played a key role in easing outbreaks in major western economies like the U.S. and the U.K., and supply of the shot is high sought after across the globe.
Kerafast. TriRadial Solutions.
Fosun Pharma (Shanghai) Biaffin. Avia Pharma – A Nordic pharma company. Auceris. Alfa Chemicals. A&C BIOBUFFER LTD. All the BioNTech Partners in the development of its vaccine are here. Sartorius Stedim Biotech. Rentschler Biopharma (Laupheim, Germany) Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech.
As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial. Under the agreement, Rentschler Biopharma will be responsible for downstream processing to provide highly purified drug substance. Process and product-related impurities will be effectively removed from the intermediate pool, which has been previously derived from mRNA synthesis.
Lipid suppliers.